Inhibrx Biosciences, Inc.
INBX
$29.59
$0.4851.67%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 25.96% | -96.24% | |||
| Gross Profit | 77.55% | 96.22% | |||
| SG&A Expenses | 6.61% | 111.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -33.13% | 337.90% | |||
| Operating Income | 36.16% | -336.59% | |||
| Income Before Tax | 33.85% | 9.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.84% | 9.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 33.84% | 9.51% | |||
| EBIT | 36.16% | -336.59% | |||
| EBITDA | 36.70% | -324.34% | |||
| EPS Basic | 33.84% | 9.52% | |||
| Normalized Basic EPS | 33.85% | -314.46% | |||
| EPS Diluted | 33.84% | 9.57% | |||
| Normalized Diluted EPS | 33.85% | -314.46% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||